CompletedPhase 1

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults

China400 participantsStarted 2025-07-06

Plain-language summary

This Phase 1, randomized, double-blind, third-party-unblinded study will be conducted at investigational sites in China. The purpose of the study is to learn about the safety and immune response of 20vPnC and 13vPnC in Chinese adults 50 years of age and older who did not receive any of pneumococcal vaccine in the past

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

.Generally healthy adults including those with preexisting stable disease determined to be eligible based on clinical assessment, medical history and clinical judgment.

Exclusion criteria

. History of microbiologically-proven invasive disease caused by Streptococcus pneumoniae
. Previous vaccination with any licensed or investigational pneumococcal vaccine or planned receipt through study participation.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Percentage of participants reporting prompted local reactions within 7 days following investigational product administration

Timeframe: Within 7 days after vaccination

Percentage of participants reporting prompted systemic events within 7 days following investigational product administration

Timeframe: Within 7 days after vaccination

Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration

Timeframe: Within 1 month after vaccination

Percentage of participants reporting serious adverse events (SAEs) throughout the study

Timeframe: Within 6 months after vaccination

Percentage of participants reporting abnormal hematology, biochemistry, and urinalysis and microscopy laboratory values

Timeframe: 3 to 5 days after vaccination

Trial details

NCT IDNCT07019909

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-01-28

View on ClinicalTrials.gov More Pneumococcal Disease trials

Plain-language summary

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

.Generally healthy adults including those with preexisting stable disease determined to be eligible based on clinical assessment, medical history and clinical judgment.

Exclusion criteria

. History of microbiologically-proven invasive disease caused by Streptococcus pneumoniae
. Previous vaccination with any licensed or investigational pneumococcal vaccine or planned receipt through study participation.

What they're measuring

Percentage of participants reporting prompted local reactions within 7 days following investigational product administration

Timeframe: Within 7 days after vaccination

Percentage of participants reporting prompted systemic events within 7 days following investigational product administration

Timeframe: Within 7 days after vaccination

Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration

Timeframe: Within 1 month after vaccination

Percentage of participants reporting serious adverse events (SAEs) throughout the study

Timeframe: Within 6 months after vaccination

Percentage of participants reporting abnormal hematology, biochemistry, and urinalysis and microscopy laboratory values

Timeframe: 3 to 5 days after vaccination